Bicara Therapeutics grants 38,950 stock options
Bicara Therapeutics Inc. director Christy J. Oliger received a grant of stock options for 38,950 shares of common stock on July 28, 2026.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Bicara Therapeutics Inc. director Christy J. Oliger received a grant of stock options for 38,950 shares of common stock on July 28, 2026. The options have an exercise price of $26.88 per share, expire on July 28, 2036, and vest one-third on July 28, 2027, with the remaining two-thirds vesting in 24 equal monthly installments, subject to her continued service.
Insider Trade Summary
Grant/Award: 38,950 shares
Grant/Award
1 txn
Insider
Oliger Christy J.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 38,950 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 38,950 contracts (Direct)
Footnotes (1)
- F1. One-third of the shares underlying this option shall vest and become exercisable on July 28, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Options Granted: 38,950 shares
Exercise Price: $26.88 per share
Expiration Date: July 28, 2036
+3 more
6 metrics
Options Granted
38,950 shares
Stock Option (Right to Buy) grant to director on July 28, 2026
Exercise Price
$26.88 per share
Exercise price of the granted stock options
Expiration Date
July 28, 2036
Expiration of the stock options granted to the director
Post-Grant Holdings
38,950 options
Total stock options held directly after the reported grant
Initial Vesting
One-third on July 28, 2027
First vesting tranche of the option award
Remaining Vesting Schedule
24 monthly installments
Remainder of options vesting after initial one-third, subject to service
Key Terms
Stock Option (Right to Buy), exercise price, vesting, expiration date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 26.8800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares underlying this option shall vest and become exercisable"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-07-28"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
derivative security financial
"transaction_type: derivative"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Bicara Therapeutics (BCAX) disclose in this Form 4?
Bicara Therapeutics reported that director Christy J. Oliger received a grant of stock options for 38,950 shares of common stock. These are derivative awards, not an open-market purchase or sale, and reflect equity-based compensation rather than cash investment or divestment.
What are the key terms of Christy J. Oliger’s stock options at BCAX?
The options cover 38,950 shares of common stock with an exercise price of $26.88 per share and an expiration date of July 28, 2036. They were granted at no cost as compensation and are exercisable only after vesting conditions are met.
How do the Bicara Therapeutics (BCAX) options granted to Christy J. Oliger vest?
One-third of the underlying 38,950 shares vest on July 28, 2027. The remaining two-thirds vest in 24 equal monthly installments after that date, conditioned on Christy J. Oliger’s continued service with Bicara Therapeutics on each vesting date.
What is Christy J. Oliger’s option position in BCAX after this grant?
Following the transaction, Christy J. Oliger holds 38,950 stock options directly, according to the filing. These options are tied to an equal number of common shares and become exercisable over time as the specified vesting schedule is satisfied.
AI-generated analysis. How Rhea-AI works. Not financial advice.
